1. Nat Chem Biol. 2019 Feb;15(2):179-188. doi: 10.1038/s41589-018-0200-7. Epub
2019  Jan 14.

Discovery of a ZIP7 inhibitor from a Notch pathway screen.

Nolin E(1), Gans S(1), Llamas L(1), Bandyopadhyay S(1), Brittain SM(1), 
Bernasconi-Elias P(1), Carter KP(2), Loureiro JJ(1), Thomas JR(1), Schirle M(1), 
Yang Y(1), Guo N(1), Roma G(3), Schuierer S(3), Beibel M(3), Lindeman A(1), 
Sigoillot F(1), Chen A(1), Xie KX(1), Ho S(1), Reece-Hoyes J(1), Weihofen WA(1), 
Tyskiewicz K(1), Hoepfner D(3), McDonald RI(1), Guthrie N(1), Dogra A(1), Guo 
H(4), Shao J(1), Ding J(1), Canham SM(1), Boynton G(1), George EL(1), Kang 
ZB(1), Antczak C(1), Porter JA(1), Wallace O(1), Tallarico JA(1), Palmer AE(2), 
Jenkins JL(1), Jain RK(1), Bushell SM(5), Fryer CJ(6).

Author information:
(1)Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
(2)Department of Chemistry and Biochemistry and BioFrontiers Institute, 
University of Colorado, Boulder, CO, USA.
(3)Novartis Institutes for Biomedical Research, Basel, Switzerland.
(4)Novartis Institutes for Biomedical Research, Shanghai, China.
(5)Novartis Institutes for Biomedical Research, Cambridge, MA, USA. 
simon.bushell@novartis.com.
(6)Novartis Institutes for Biomedical Research, Cambridge, MA, USA. 
christy.fryer@novartis.com.

The identification of activating mutations in NOTCH1 in 50% of T cell acute 
lymphoblastic leukemia has generated interest in elucidating how these mutations 
contribute to oncogenic transformation and in targeting the pathway. A 
phenotypic screen identified compounds that interfere with trafficking of Notch 
and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism. Target 
identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport 
family member, in governing Notch trafficking and signaling. Generation and 
sequencing of a compound-resistant cell line identified a V430E mutation in ZIP7 
that confers transferable resistance to the compound NVS-ZP7-4. NVS-ZP7-4 
altered zinc in the ER, and an analog of the compound photoaffinity labeled ZIP7 
in cells, suggesting a direct interaction between the compound and ZIP7. 
NVS-ZP7-4 is the first reported chemical tool to probe the impact of modulating 
ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch 
pathway.

DOI: 10.1038/s41589-018-0200-7
PMCID: PMC7251565
PMID: 30643281 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests E.N., S.G., L.L., S.B., S.M. 
Brittain, P.B.-E., J.J.L., J.R.T., M.S., Y.Y., N.G., G.R., S.S., M.B., A.L., 
F.S., A.C., K.X.X., S.H., J.R.-H., W.A.W., K.T., D.H., R.I.M., N.G., A.D., H.G., 
J.S., J.D., S.M.C., G.B., E.L.G., Z.B.K., C.A., J.A.P., O.W., J.A.T., J.L.J., 
R.K.J., S.M. Bushell, and C.J.F. are (or were at the time the research was 
conducted) employees of Novartis.